• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Alcon unveils thermal pulsation system for meibomian gland disfunction

Article

The company’s Systane iLux2 Meibomian Gland Dysfunction Thermal Pulsation System is a handheld device that allows patients to see the need for treatment and visualize their procedure.

Alcon this week unveiled its Systane iLux2 Meibomian Gland Dysfunction (MGD) Thermal Pulsation System.

According to the company, with new imaging technology to capture infrared photos and HD video of the meibomian glands, this all-in-one handheld device allows patients to see the need for treatment and visualize their procedure, and experience results in as little as one week.1

“Alcon is dedicated to the advancement of medical device technology and providing Eye Care Professionals (ECPs) with the tools needed to effectively treat their patients,” Fred Ellis, vice president of US Pharmaceutical and Dry Eye, Alcon, said in a statement. “With the Systane iLux2 MGD Thermal Pulsation System, ECPs will be able to further patient trust and confidence because seeing is believing.”

The company pointed out that the Systane iLux2 MGD Thermal Pulsation System expands Alcon’s current dry eye treatment offerings and allows practitioners to tailor MGD treatment to the needs of each of their patients in 8 to 12 minutes.1,2

  • The device’s imaging technology allows patients to view both their meibomian glands and treatment through infrared imaging and HD video of the procedure.
  • ECPs can customize heat and compression across each easy-to-visualize treatment zone.

According to Alcon, Systane iLux2 MGD Thermal Pulsation System can help Eye Care Practitioners build a strong, trusting relationship with their patients by boosting the credibility of their treatment recommendation through direct visualization of the disease and tracking the disease over time through stored meibomian gland images.

Eric D. Donnenfeld, MD, FAAO, Ophthalmic Consultants of Long Island, NY, pointed out that 56% of MGD patients see 4 or more eye care practitioners in search of proper diagnosis and relief.3

This is a prevalent diagnosis in my practice, and it is essential for me to stay on top of the latest treatment options,”Donnenfeld said in a statement. “The new Systane iLux2 MGD Thermal Pulsation System gives me the confidence to customize treatments based on my patients’ needs and help them see, understand and value their MGD treatment.”

References
1. Tauber J, Owen J, Bloomenstein M, Hovanesian J, Bullimore MA. Comparison of the iLux and the LipiFlow for the Treatment of Meibomian Gland Dysfunction and Symptoms: A Randomized Clinical Trial. Clin Ophthalmol. 2020;14:405-418.
2. Alcon data on file, 2019.
3. The Dry Eye Problem. Building Your Dry Eye Center of Excellence. Review of Optometric Business supplement. https://www.reviewob.com/building-your-dry-eye-center-of-excellence/. Accessed April 4, 2022.
Related Videos
© 2024 MJH Life Sciences

All rights reserved.